Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Metformin Lowers Cancer Risk by Preventing Formation of Reactive Oxygen Species

By LabMedica International staff writers
Posted on 09 Feb 2012
The drug metformin, which is used to treat type II diabetes, has been found to reduce cancer risk by blocking the formation of reactive oxygen species (ROS) that cause the type of DNA damage that leads to tumor development.

Metformin is used alone or with other medications, including insulin, to treat type II diabetes. More...
The drug helps to control the amount of glucose in the blood by decreasing the amount of glucose absorbed from food and the amount of glucose made by the liver. Metformin also increases the body's response to insulin. Metformin is not used to treat type I diabetes where the body does not produce insulin due to autoantibodies that attack pancreatic beta cells.

Investigators at McGill University (Montreal, Canada) and the University of Montreal (Canada) reported in the January 18, 2012, online edition of the journal Cancer Prevention Research that they had found that metformin attenuated elevations in ROS and related DNA damage and mutations induced by exposure to the toxic herbicide paraquat. However, the drug had no effect on similar changes induced by hydrogen peroxide, indicating a reduction in endogenous ROS production. Importantly, metformin also inhibited Ras-induced ROS production and DNA damage.

“It is remarkable that metformin, an inexpensive, off-patent, safe and widely used drug, has several biological actions that may result in reduced cancer risk – these latest findings suggest that it reduces mutation rate in somatic cells, providing an additional mechanism by which it could prevent cancer,” said senior author Dr. Michael Pollak, professor of medicine and oncology at McGill University.

“This study opens an exciting new direction in cancer-prevention research,” said Dr. Pollak. “This does not imply, however, that metformin is now ready to be widely used for cancer prevention. We do not yet know if the drug accumulates to sufficient concentrations in human tissues at risk for cancer, such as breast or colon, when taken at the usual doses used for diabetes treatment, nor do we know if the findings from the original studies showing reduced cancer risk, which were carried out in diabetics, also apply to people without diabetes. But the possibility of protecting DNA from oxidative damage by the use of a well-tolerated drug was not expected, and this topic now needs further study at many levels.”

Related Links:
McGill University
University of Montreal


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.